IDEXX Laboratories stock rebounded from a post-earnings selloff. The company recently beat quarterly earnings estimates and provided strong FY2026 guidance. Wealthfront Advisers LLC increased its stake in the company by 35.1%, purchasing 2,463 additional shares for a total holding of 9,477 shares valued at $6.055 million. Simultaneously, EVP George Fennell sold a significant portion of his holdings, reducing 11,345 shares and decreasing his ownership by over 50%. The analyst consensus rating on the stock is Moderate Buy with an average price target of $783.33. The headline indicates the rebound occurred with no new catalyst identified beyond the previous earnings results and guidance.
Read full analysisIDEXX Laboratories stock rebounded from a post-earnings selloff. The company recently beat quarterly earnings estimates and provided strong FY2026 guidance. Wealthfront Advisers LLC increased its stake in the company by 35.1%, purchasing 2,463 additional shares for a total holding of 9,477 shares valued at $6.055 million. Simultaneously, EVP George Fennell sold a significant portion of his holdings, reducing 11,345 shares and decreasing his ownership by over 50%. The analyst consensus rating on the stock is Moderate Buy with an average price target of $783.33. The headline indicates the rebound occurred with no new catalyst identified beyond the previous earnings results and guidance.
IDEXX Laboratories is a leading provider of diagnostic products and services for veterinary practices, including blood analyzers, reference lab testing, and practice management software. The company benefits from rising pet ownership and increasing spending on pet healthcare. IDXX has been under pressure since early February after Q4 earnings guidance failed to excite investors, and today's move appears to be a partial recovery from that selloff.